Cytek Biosciences Inc (CTKB)

Debt-to-capital ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	393,064	415,524	424,179	423,460	425,546	416,509	411,129	407,442	405,385	403,195	-10,985
Debt-to-capital ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $393,064K)
= 0.00

The debt-to-capital ratio for Cytek Biosciences Inc has consistently been 0.00 for the past 11 quarters, indicating that the company has not utilized any debt to finance its operations relative to its total capital structure during this period. A debt-to-capital ratio of 0.00 implies that the company's total debt is negligible or non-existent compared to its total capital, which includes both debt and equity. This could suggest that Cytek Biosciences has been relying primarily on equity financing or internally generated funds to support its business activities, rather than taking on debt obligations. While a low debt-to-capital ratio can signal a strong financial position and lower financial risk, it may also indicate that the company is not leveraging debt as a potential source of capital for growth or expansion. Analysts may want to further investigate the reasons behind Cytek Biosciences' consistent zero debt-to-capital ratio to understand its capital structure strategy and implications for future financial performance and growth opportunities.